Cargando…
Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age
PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AA...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953441/ https://www.ncbi.nlm.nih.gov/pubmed/31770057 http://dx.doi.org/10.1200/JCO.19.02208 |
_version_ | 1783486624163692544 |
---|---|
author | Rank, Cecilie U. Wolthers, Benjamin O. Grell, Kathrine Albertsen, Birgitte K. Frandsen, Thomas L. Overgaard, Ulrik M. Toft, Nina Nielsen, Ove J. Wehner, Peder S. Harila-Saari, Arja Heyman, Mats M. Malmros, Johan Abrahamsson, Jonas Norén-Nyström, Ulrika Tomaszewska-Toporska, Beata Lund, Bendik Jarvis, Kirsten B. Quist-Paulsen, Petter Vaitkevičienė, Goda E. Griškevičius, Laimonas Taskinen, Mervi Wartiovaara-Kautto, Ulla Lepik, Kristi Punab, Mari Jónsson, Ólafur G. Schmiegelow, Kjeld |
author_facet | Rank, Cecilie U. Wolthers, Benjamin O. Grell, Kathrine Albertsen, Birgitte K. Frandsen, Thomas L. Overgaard, Ulrik M. Toft, Nina Nielsen, Ove J. Wehner, Peder S. Harila-Saari, Arja Heyman, Mats M. Malmros, Johan Abrahamsson, Jonas Norén-Nyström, Ulrika Tomaszewska-Toporska, Beata Lund, Bendik Jarvis, Kirsten B. Quist-Paulsen, Petter Vaitkevičienė, Goda E. Griškevičius, Laimonas Taskinen, Mervi Wartiovaara-Kautto, Ulla Lepik, Kristi Punab, Mari Jónsson, Ólafur G. Schmiegelow, Kjeld |
author_sort | Rank, Cecilie U. |
collection | PubMed |
description | PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse. CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse. |
format | Online Article Text |
id | pubmed-6953441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Clinical Oncology |
record_format | MEDLINE/PubMed |
spelling | pubmed-69534412021-01-10 Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age Rank, Cecilie U. Wolthers, Benjamin O. Grell, Kathrine Albertsen, Birgitte K. Frandsen, Thomas L. Overgaard, Ulrik M. Toft, Nina Nielsen, Ove J. Wehner, Peder S. Harila-Saari, Arja Heyman, Mats M. Malmros, Johan Abrahamsson, Jonas Norén-Nyström, Ulrika Tomaszewska-Toporska, Beata Lund, Bendik Jarvis, Kirsten B. Quist-Paulsen, Petter Vaitkevičienė, Goda E. Griškevičius, Laimonas Taskinen, Mervi Wartiovaara-Kautto, Ulla Lepik, Kristi Punab, Mari Jónsson, Ólafur G. Schmiegelow, Kjeld J Clin Oncol ORIGINAL REPORTS PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored. PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol. RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse. CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse. American Society of Clinical Oncology 2020-01-10 2019-11-26 /pmc/articles/PMC6953441/ /pubmed/31770057 http://dx.doi.org/10.1200/JCO.19.02208 Text en © 2019 by American Society of Clinical Oncology http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Rank, Cecilie U. Wolthers, Benjamin O. Grell, Kathrine Albertsen, Birgitte K. Frandsen, Thomas L. Overgaard, Ulrik M. Toft, Nina Nielsen, Ove J. Wehner, Peder S. Harila-Saari, Arja Heyman, Mats M. Malmros, Johan Abrahamsson, Jonas Norén-Nyström, Ulrika Tomaszewska-Toporska, Beata Lund, Bendik Jarvis, Kirsten B. Quist-Paulsen, Petter Vaitkevičienė, Goda E. Griškevičius, Laimonas Taskinen, Mervi Wartiovaara-Kautto, Ulla Lepik, Kristi Punab, Mari Jónsson, Ólafur G. Schmiegelow, Kjeld Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age |
title | Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age |
title_full | Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age |
title_fullStr | Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age |
title_full_unstemmed | Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age |
title_short | Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age |
title_sort | asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the nopho all2008 treatment of patients 1-45 years of age |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953441/ https://www.ncbi.nlm.nih.gov/pubmed/31770057 http://dx.doi.org/10.1200/JCO.19.02208 |
work_keys_str_mv | AT rankcecilieu asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT wolthersbenjamino asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT grellkathrine asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT albertsenbirgittek asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT frandsenthomasl asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT overgaardulrikm asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT toftnina asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT nielsenovej asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT wehnerpeders asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT harilasaariarja asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT heymanmatsm asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT malmrosjohan asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT abrahamssonjonas asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT norennystromulrika asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT tomaszewskatoporskabeata asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT lundbendik asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT jarviskirstenb asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT quistpaulsenpetter asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT vaitkevicienegodae asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT griskeviciuslaimonas asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT taskinenmervi asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT wartiovaarakauttoulla asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT lepikkristi asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT punabmari asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT jonssonolafurg asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage AT schmiegelowkjeld asparaginaseassociatedpancreatitisinacutelymphoblasticleukemiaresultsfromthenophoall2008treatmentofpatients145yearsofage |